European Countries Consider Bans on Ozempic Amid Supply Shortages and Side Effect Concerns

The American Medical Association Calls for Full Coverage of Obesity Treatments as Demand Soars

Germany's drug regulator is considering a ban on the export of Novo Nordisk's diabetes drug Ozempic, due to its increased use for weight loss causing supply shortages for diabetes patients.
Belgium has temporarily banned the use of Ozempic for weight loss until summer 2024, due to a shortage of the drug.
Ozempic and its sister drug Wegovy have seen a surge in demand due to their weight-loss benefits, leading to shortages that could last for years, according to Novo Nordisk's CEO.
The American Medical Association has called for insurance companies and federal payers to fully cover obesity treatments like Wegovy and Ozempic.
Concerns have been raised about the side effects of Ozempic, with some patients reporting severe gastrointestinal problems.